Logo image of VRDN

VIRIDIAN THERAPEUTICS INC (VRDN) Stock Fundamental Analysis

NASDAQ:VRDN - Nasdaq - US92790C1045 - Common Stock

18.1  -0.31 (-1.68%)

Fundamental Rating

3

VRDN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While VRDN seems to be doing ok healthwise, there are quite some concerns on its profitability. VRDN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRDN had negative earnings in the past year.
VRDN had a negative operating cash flow in the past year.
In the past 5 years VRDN always reported negative net income.
VRDN had a negative operating cash flow in each of the past 5 years.
VRDN Yearly Net Income VS EBIT VS OCF VS FCFVRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -33.31%, VRDN is in the better half of the industry, outperforming 64.07% of the companies in the same industry.
The Return On Equity of VRDN (-36.34%) is better than 74.34% of its industry peers.
Industry RankSector Rank
ROA -33.31%
ROE -36.34%
ROIC N/A
ROA(3y)-39.1%
ROA(5y)-67.96%
ROE(3y)-42.99%
ROE(5y)-97.25%
ROIC(3y)N/A
ROIC(5y)N/A
VRDN Yearly ROA, ROE, ROICVRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRDN Yearly Profit, Operating, Gross MarginsVRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

5

2. Health

2.1 Basic Checks

VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRDN has more shares outstanding than it did 1 year ago.
VRDN has more shares outstanding than it did 5 years ago.
VRDN has a worse debt/assets ratio than last year.
VRDN Yearly Shares OutstandingVRDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
VRDN Yearly Total Debt VS Total AssetsVRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 11.84 indicates that VRDN is not in any danger for bankruptcy at the moment.
VRDN has a better Altman-Z score (11.84) than 87.26% of its industry peers.
VRDN has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
VRDN's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. VRDN outperforms 40.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 11.84
ROIC/WACCN/A
WACC11.11%
VRDN Yearly LT Debt VS Equity VS FCFVRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 18.55 indicates that VRDN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 18.55, VRDN belongs to the top of the industry, outperforming 93.98% of the companies in the same industry.
A Quick Ratio of 18.55 indicates that VRDN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 18.55, VRDN belongs to the top of the industry, outperforming 93.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.55
Quick Ratio 18.55
VRDN Yearly Current Assets VS Current LiabilitesVRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.49% over the past year.
Looking at the last year, VRDN shows a very negative growth in Revenue. The Revenue has decreased by -13.71% in the last year.
The Revenue for VRDN have been decreasing by -48.16% on average. This is quite bad
EPS 1Y (TTM)15.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.5%
Revenue 1Y (TTM)-13.71%
Revenue growth 3Y-33.13%
Revenue growth 5Y-48.16%
Sales Q2Q%19.44%

3.2 Future

The Earnings Per Share is expected to grow by 15.45% on average over the next years. This is quite good.
Based on estimates for the next years, VRDN will show a very strong growth in Revenue. The Revenue will grow by 346.51% on average per year.
EPS Next Y23.59%
EPS Next 2Y9.34%
EPS Next 3Y7.55%
EPS Next 5Y15.45%
Revenue Next Year-16.02%
Revenue Next 2Y-21.66%
Revenue Next 3Y370.16%
Revenue Next 5Y346.51%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRDN Yearly Revenue VS EstimatesVRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
VRDN Yearly EPS VS EstimatesVRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRDN Price Earnings VS Forward Price EarningsVRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRDN Per share dataVRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.34%
EPS Next 3Y7.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRDN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (1/22/2025, 10:40:03 AM)

18.1

-0.31 (-1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners92.84%
Inst Owner Change0.01%
Ins Owners0.04%
Ins Owner Change1.15%
Market Cap1.43B
Analysts85.22
Price Target41.25 (127.9%)
Short Float %15.78%
Short Ratio8.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.57%
Min EPS beat(2)-12.54%
Max EPS beat(2)-6.6%
EPS beat(4)1
Avg EPS beat(4)-5.31%
Min EPS beat(4)-31.95%
Max EPS beat(4)29.83%
EPS beat(8)3
Avg EPS beat(8)-13.6%
EPS beat(12)5
Avg EPS beat(12)-11.68%
EPS beat(16)6
Avg EPS beat(16)-74.52%
Revenue beat(2)1
Avg Revenue beat(2)33.07%
Min Revenue beat(2)-18.06%
Max Revenue beat(2)84.21%
Revenue beat(4)1
Avg Revenue beat(4)2.39%
Min Revenue beat(4)-55.77%
Max Revenue beat(4)84.21%
Revenue beat(8)1
Avg Revenue beat(8)-23.32%
Revenue beat(12)3
Avg Revenue beat(12)3.9%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.46%
PT rev (3m)3.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.98%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-51.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4747.35
P/FCF N/A
P/OCF N/A
P/B 2.03
P/tB 2.03
EV/EBITDA N/A
EPS(TTM)-4.31
EYN/A
EPS(NY)-4.28
Fwd EYN/A
FCF(TTM)-2.49
FCFYN/A
OCF(TTM)-2.49
OCFYN/A
SpS0
BVpS8.93
TBVpS8.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.31%
ROE -36.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.1%
ROA(5y)-67.96%
ROE(3y)-42.99%
ROE(5y)-97.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.21%
Cap/Sales 147.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.55
Quick Ratio 18.55
Altman-Z 11.84
F-Score4
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)254.35%
Cap/Depr(5y)161.46%
Cap/Sales(3y)114.22%
Cap/Sales(5y)69.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.5%
EPS Next Y23.59%
EPS Next 2Y9.34%
EPS Next 3Y7.55%
EPS Next 5Y15.45%
Revenue 1Y (TTM)-13.71%
Revenue growth 3Y-33.13%
Revenue growth 5Y-48.16%
Sales Q2Q%19.44%
Revenue Next Year-16.02%
Revenue Next 2Y-21.66%
Revenue Next 3Y370.16%
Revenue Next 5Y346.51%
EBIT growth 1Y-21.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.88%
EBIT Next 3Y-11.68%
EBIT Next 5Y43.08%
FCF growth 1Y-156.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-158.07%
OCF growth 3YN/A
OCF growth 5YN/A